Tag Archives: Gilead Sciences

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India  MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

India rejects Gilead’s Hepatitis C drug patent request

Source: Reuters 15 Jan 2015 (Reuters) – India’s patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine. … Continue reading

Posted in Generics, Hepatitis C, Indian Patent Law, Patents, Sofosbuvir | Tagged , , , | Leave a comment

Egypt starts distributing Hepatitis C drug

Ahram Online , Thursday 16 Oct 2014 Egypt has started distributing Sovaldi, a drug for treating Hepatitis C. Health Minister Adel Adawi announced at a press conference on Thursday that a new national plan was underway for the prevention of … Continue reading

Posted in Hepatitis C, Pricing | Tagged , | Leave a comment

Civil society opposes patent on sofosbuvir

Source: Lawyers Collective 10 September, 2014- In a move towards furthering access to affordable medicines, Lawyers Collective through Sankalp Rehabilitation Trust, the Hepatitis Coalition of Nagaland and Network of PLHIV living in the Asia Pacific region (APN+), filed a pre- … Continue reading

Posted in Hepatitis C, Patent Opposition, Patents | Tagged , | Leave a comment